Pharmosa Biopharm Inc., a biotechnology company, focuses on research and development of new drugs in Taiwan. The company develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease, which has completed a Phase I clinical trial. The company was formerly known as Pharmosa Limited and changed its name to Pharmosa Biopharm Inc. in October 2016. Pharmosa Biopharm Inc. was incorporated in 2000 and is headquartered in Taipei, Taiwan.
Frequently asked questions
What sector does Pharmosa Biopharm Inc. (6875) operate in?
Pharmosa Biopharm Inc. belongs to the Other sector and operates in the Biotechnology industry.
What is Pharmosa Biopharm Inc. (6875) current stock price?
As of the latest data, Pharmosa Biopharm Inc. stock price is NT$32.25, with a previous close of NT$32.15. Pharmosa Biopharm Inc. gained NT$0.10 in the last trading session, representing a 0.31% increase.
What is Pharmosa Biopharm Inc. (6875) current market capitalization?
Pharmosa Biopharm Inc. market cap is approximately 4.17 billion.
What is Pharmosa Biopharm Inc. (6875) Earnings Per Share (EPS)?
The trailing EPS is -NT$2.97.
Does Pharmosa Biopharm Inc. (6875) pay dividends?
No. Pharmosa Biopharm Inc. does not pay a dividend.
What is Pharmosa Biopharm Inc. (6875) beta (volatility) score?
Pharmosa Biopharm Inc. has a beta of 0.155, indicating lower volatility than the overall market.
